title: An increase in endogenous erythropoietin concentrations has no cardioprotective effects in patients undergoing coronary artery bypass graft surgery.
abstract: OBJECTIVE
  Preliminary data showed an increase in endogenous erythropoietin (EPO) concentrations after acute normovolemic hemodilution (ANH) in patients undergoing coronary artery bypass graft (CABG) surgery. Numerous studies have shown the organ protective properties of EPO. The aim of this study was to investigate the cardioprotective effects of these increased EPO concentrations that resulted from ANH during cardiac surgery.
  
  
  METHODS
  A prospective, randomized, blind study.
  
  
  METHODS
  A university hospital.
  
  
  METHODS
  A total of 93 patients undergoing isolated CABG surgery with or without cardiopulmonary bypass (CPB).
  
  
  METHODS
  Subjects with CPB were randomized into the control (C) or ANH group. Those in the off-pump coronary artery bypass group underwent no treatment. In the ANH group, a precalculated amount of blood was withdrawn and replaced by colloids after the induction of anesthesia.
  
  
  RESULTS
  Hemodynamic parameters were recorded intra- and postoperatively. Troponin concentrations were measured as a routine parameter postoperatively. Upon intensive care unit arrival, the EPO levels were higher in the ANH group than in the C group. There was no significant difference between the troponin values of the C and the ANH groups at 4 hours postoperatively.
  
  
  CONCLUSIONS
  In patients undergoing CABG surgery on CPB, an increase in endogenous EPO concentrations in the physiologic range has no cardioprotective effects.
authors.affiliation: Department of Anesthesiology, Université Catholique de Louvain, Cliniques Universitaires Saint Luc, Brussels, Belgium. mona.momeni@uclouvain.be
authors.forename: Mona
authors.initials: M
authors.lastname: Momeni
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Liistro
authors.forename: Philippe
authors.initials: P
authors.lastname: Baele
authors.forename: Amine
authors.initials: A
authors.lastname: Matta
authors.forename: David
authors.initials: D
authors.lastname: Kahn
authors.forename: Michel
authors.initials: M
authors.lastname: Van Dyck
authors.forename: Marc
authors.initials: M
authors.lastname: De Kock
authors.forename: Laurent
authors.initials: L
authors.lastname: De Kerchove
authors.forename: David
authors.initials: D
authors.lastname: Glineur
authors.forename: Dominique
authors.initials: D
authors.lastname: Thiry
authors.forename: André
authors.initials: A
authors.lastname: Gregoire
authors.forename: Luc-Marie
authors.initials: LM
authors.lastname: Jacquet
authors.forename: Fatima
authors.initials: F
authors.lastname: Laarbui
authors.forename: Christine
authors.initials: C
authors.lastname: Watremez
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D002316:Cardiotonic Agents / Q000097:blood; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D004921:Erythropoietin / Q000097:blood*; D005260:Female; D006438:Hemodilution / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D016343:Monitoring, Intraoperative / Q000379:methods; D019990:Perioperative Care / Q000379:methods*; D011182:Postoperative Care / Q000379:methods*; D011446:Prospective Studies; D016037:Single-Blind Method
chemical_list: D015415:Biomarkers; D002316:Cardiotonic Agents; D004921:Erythropoietin